Health Information Services
Indegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor
Indegene Limited (INDGN) announced as the first industry partner for the Indo-UK Life Science Corridor, connecting India and UK research.
Indegene Limited (INDGN) has been announced as the first industry partner for the Indo-UK Life Science Corridor, a collaboration between the Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London. This initiative, supported by the Imperial Global India initiative, aims to connect world-class research in India and the UK with entrepreneurship, industry expertise, and pathways to translation. The corridor is designed to facilitate the two-way sharing of knowledge and evidence on priority challenges, innovation readiness, and ecosystem needs.
Strategic Collaboration
Indegene, C-CAMP, and Imperial College London will co-develop entrepreneurship programs and support the exchange of knowledge and talent between India and the UK. Indegene, an AI-native operating partner for modern life sciences, brings deep industry context to the corridor and has a track record of working with the world’s top 20 biopharma companies. As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programs.
Focus Areas
Initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science, and mental health. The three organizations made the announcement at the C-CAMP–Imperial joint Roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.
The partnership reflects Indegene’s commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale. This collaboration is expected to produce smarter, more scalable, and more accessible innovations relevant to both populations.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 15.9% over three months and trades near its 52-week highs. The PEG of 2.41 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 2.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.9% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
Health Information Services
Indegene Limited (indgn) Q2 FY27: Revenue Up 39.5% Yoy, H1 USD Revenue Growth at Four-year High
Indegene Limited (INDGN) reports strong Q2 FY27 performance with 39.5% YoY revenue growth and H1 USD revenue hitting a four-year high.
Indegene Limited (INDGN), the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026. Indegene’s Q2 FY27 performance showcased a robust revenue growth of 39.5% year-on-year (YoY) in INR, translating to a 27.5% YoY increase in USD. This marks the fifth successive quarter of above 5% sequential growth. The company’s revenue for the quarter stood at ₹11,223 million ($117.5 million), with an EBITDA of ₹1,873 million, marking a 32.0% YoY increase. Moreover, H1 USD revenue growth reached a four-year high, reflecting the company’s sustained deal momentum and favorable industry tailwinds.
Revenue and Profitability
Indegene’s revenue from operations increased significantly to ₹11,223 million, up from ₹8,042 million in the same quarter last year. The company’s EBITDA margin remained stable at 16.7%, despite wage hikes, while the profit after tax (PAT) grew by 10% YoY to ₹1,123 million. This strong performance is attributed to the expansion across top accounts and an increase in the number of $1 million+ clients to 59, including 13 in the $10M+ range.
Growth and Future Outlook
Manish Gupta, Chairman and CEO of Indegene, highlighted the company’s broad-based growth driven by expansion across top accounts and significant deal wins in GenAI-enabled transformation and upstream engagements. Suhas Prabhu, CFO, noted that with a healthy pipeline and sustained deal momentum, Indegene expects growth and margin expansion to come together in the second half. The company anticipates EBITDA to grow faster than revenue in the coming quarters, supported by higher yields on investments and lower amortization.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
Health Information Services
Sagility Limited (NSE: Sagility) Q2 FY27: 11.9% Y-o-y Constant Currency Organic Growth
Sagility Limited (NSE: SAGILITY) reports Q2 FY27 results with 11.9% Y-o-Y constant currency organic growth and $40.2M ACV.
Sagility Limited (NSE: SAGILITY) has announced its Q2 FY27 results, showcasing robust performance with 11.9% year-over-year constant currency organic growth. The company won $40.2M in ACV from 31 existing clients and 1 new logo, indicating increasing traction in larger deals.
Financial Highlights
The financial performance highlights include a revenue of ₹ 20,321 Million, an Adjusted EBITDA of ₹ 5,353 Million, and an Adjusted PAT of ₹ 3,254 Million. The company’s margin stood at 26.3% for Adjusted EBITDA and 16.0% for Adjusted PAT.
Growth and Expansion
Sagility’s growth is further supported by its acquisition of Chirok Health LLC, which adds specialized CDI and coding capabilities, extending its end-to-end RCM offering and unlocking new growth opportunities. The acquisition is expected to broaden Sagility’s provider footprint and deliver greater client value.
As a result, Sagility continues to strengthen its market position and drive forward-looking growth prospects.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of SAGILITY LIMITED
SAGILITY LIMITED belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
SAGILITY rises 8.5% over three months, with buying pressure holding steady. The PEG of 0.25 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.5% and profits at 86.1% CAGR. That is strong double-digit growth on both counts. The stock holds at 43% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Revenue grows at 19.5% and profits at 86.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of SAGILITY LIMITED.
Health Information Services
Indegene Limited (indgn) Wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition
Indegene Limited (INDGN) wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-powered pharma commercialization.
Indegene Limited (INDGN) has been honored with Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for its outstanding achievements in AI-powered pharma commercialization. This recognition underscores Indegene’s leadership in transforming pharmaceutical commercialization workflows through domain-led AI, knowledge orchestration, and integrated execution.
Recognition Highlights
Frost & Sullivan commends Indegene for its ability to align its AI strategy with the evolving needs of the pharmaceutical industry while executing at scale across commercial, medical, regulatory, safety, analytics, content, and field engagement workflows. The recognition highlights Indegene’s leadership in modernizing complex commercialization processes through domain expertise, technology, data, and execution support.
Innovative Approach
Indegene’s Pharma Operating System (OS) connects business decisions, workflow execution, and intelligence across the enterprise, helping pharmaceutical organizations replace fragmented processes with integrated and adaptive operating models. Its Cortex life sciences-native reasoning engine enables subject matter experts to codify specialized knowledge, creating validated knowledge graphs and guiding AI-enabled workflows.
Forward-Looking Strategy
The company’s commitment to customer experience strengthens its market position by connecting strategy, data, content, execution, and measurable outcomes. Indegene’s platform-agnostic approach allows customers to work in existing technology environments, reducing adoption friction while protecting existing technology investments. This recognition reinforces Indegene’s belief in the next wave of value creation through connecting intelligence, decisions, and execution across the enterprise.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
-
Consumer Cyclical3 days agoUflex Limited (NSE: Uflex) Q2 FY27: Strong Performance Amidst Geopolitical Headwinds
-
Consumer Cyclical3 days agoUflex Limited (NSE: Uflex) Q2 FY27: Revenue Up 26.1%, PAT Surges 682.8%
-
GUJTHEM3 days agoGujarat Themis Biosyn Limited Announces Strategic Acquisition of Microbiopharm Japan
-
Asset Management3 days agoNuvama Wealth Management Limited Q2 FY27: Operating Profit Up 26% Yoy
-
Biotechnology3 days agoDishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
-
Industrials3 days agoOne Point One Solutions Limited Secures NSDL Mandate, Expanding Integrated Enterprise Operations and Technology Footprint
-
Energy3 days agoUnited Drilling Tools Limited UNIDT Q2 FY27: Maintains Profitability Amidst Market Challenges
-
Computer Hardware3 days agoTvs Electronics Limited (tvselect) Q2/h1-fy27 Earnings Presentation: Revenue Rebounds, Margins Under Pressure
